BiodefenseAnthrax vaccine contract worth up to $1.25 billion over five years
Emergent BioSolutions has been awarded a contract to supply the U.S. government with FDA-licensed anthrax vaccine; the 5-year contract a has a total value of up to $1.25 billion; the first 8.5 million doses will be delivered before the end of the year
Rockville, Maryland-based Emergent BioSolutions Inc. announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is proud to be able to contribute to the U.S. government’s program of protecting the nation from the threat of anthrax,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “This 5-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs. In coming to agreement, Emergent and the Centers for Disease Control and Prevention worked diligently to establish business terms that incorporate substantial price concessions.”
Initial deliveries under this award are expected to begin in 2011 with 8.5 million doses scheduled to be delivered during the first contract year. Deliveries are scheduled to continue, subject to availability of funding, through September 2016. The company says it retains the ability to modify the timing of deliveries depending on manufacturing yields and other factors.
